Articles On Medical Developments International (ASX:MVP)

Pfizer has won a spirited bidding war for the GLP-1 drug developer Metsera Pharmx launches its eBay for chemists Gough-era biotech stocks maintain the rage     A fierce US$10 billion bidding war for the Nasdaq-listed anti-obesity drug mak...

Catapult Group is buying a German soccer analytics and talent scouting firm for $140 million PainChek signs its maiden US aged-care client Biotechs flock to the funding well – with more raisings to come   A global leader in athlete health...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin FNArena's Monitor keeps track of corporate earnings result releases, including broke...

Artrya shares surge up to 42% on FDA clearance of the company’s Salix Coronary Plaque device Sonic Healthcare joins CSL in the healthcare sin bin Universal Biosensors calls in the corporate undertakers   Artrya (ASX:AYA) has won US Food a...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin A strong finish to Wall Street on Friday has set the Australian market up for a posi...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin US markets racheted up another rally, making it eight consecutive positive days. Aft...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 8114.00 + 28.00 0.35% S&P ASX 200 8126.20 +...

Highlights Several ASX-listed companies across diverse sectors are estimated to be trading below their intrinsic value Key businesses in infrastructure, diagnostics, and consumer services sectors reflect marked discount based on...

Highlights: Domino's Pizza Enterprises is priced below its estimated fair value based on cash flow metrics. LaserBond and Acrow show substantial gaps between market price and fair value estimates. Several industrial and heal...

Aroa says the real impact from the 10% US tariff imposed on New Zealand goods will be much less than that Quarter time scores show companies are kicking with the wind Dimerix shares enter trading halt ahead of licensing deal   Kiwi wounds...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin US markets were volatile in overnight trade as participants digest the flow of tarif...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin With apologies: we are experiencing tech problems this morning with some of the over...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Momentum buyers chased stocks higher for the third day despite ongoing tariff and ec...

Healthcare leaders stress need for more women in leadership in ASX biotech sector ImpediMed’s female CEO and chair understand challenges for women in sector Dimerix CEO and MD Dr Nina Webster believes workplace flexibility helps women bala...

ASX healthcare leaders are often involved in multiple companies or organisations  Syntara CEO Gary Philips believes seasoned executives can help develop the sector in Australia Dimerix CEO and MD Dr Nina Webster has two other key positions...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

The S&P/ASX 200 rose 5% in January to reach a new record high Utilities was the only sector to fall in January with financials the top performer AusQuest tops January winners up 388% with discovery of a large-scale Peruvian copper pros...

Highlights: Medical Developments International (ASX:MVP) trades at a low P/S ratio. Revenue growth has been slower compared to the industry. Future growth expectations remain modest. Medical Developments International Limited...

No company wants sub-optimal returns on their product – and pain-management house Medical Developments International (ASX:MVP) is no exception. For some years, management has believed that customers undervalued the worth of its flagship pro...

Looking for standout ASX healthcare stocks? Top brokers have you covered, rating three names as potential buys for FY25. Pro Medicus Ltd (ASX: PME), Fisher & Paykel Healthcare Corp Ltd (ASX: FPH), and Ansell Ltd (ASX: ANN) are the t...

Asthma affects hundreds of millions of people globally While inhalers are effective, people are not taking them correctly Adherium addresses this problem, as we reached out to CEO Paul Mastoridis   It’s one of the most common chronic dise...

If you’re wanting a little exposure to the small side of the market, then it could be worth checking out the two small cap ASX shares that Bell Potter rates as a buy. Here’s what the broker is saying about them: Ai-Media Technologies...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AGI)) - Ainsworth Game Technology ((ALX)) - Atlas Arteria ((ATA)) - Atturra ((AUA)) - Audeara ((ASB)) - Austal ((BUB)) - Bubs Australia ((CCX))...

Imricor establishes first iCMR site in Switzerland MVP to seek market opportunities in the US  Nyrada delays launch of Phase I/IIa study   Imricor signs with University Hospital Lausanne MRI-compatible medical devices specialist Imricor M...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Medical Developments International (MVP) cancels plans for clinical trials of its Penthrox drug in China and subsequent commercial launch in the country MVP says “extended delays” to the expected timeline for clinical trial outcomes was...

The PolyNovo Ltd (ASX: PNV) share price is coming under pressure today as the S&P/ASX 300 Index (ASX: XKO) faces another sea of red. At the time of writing, the PolyNovo share price has slid 5.7% to last change hands at $1.65 apiece. M...

As nerves mount for players on both NRL Grand Final sides preparing to line up at Staiudm Australia on Sunday night, it’s worth remembering the myriad enterprises that enable sportspeople to leap higher and kick further – while also tending...

The Medical Developments International Ltd (ASX: MVP) share price is up 4.6% as we head into the lunch hour. Medical Developments shares closed yesterday at $1.85 and are currently trading for $1.93. The ASX healthcare company, focused on...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. Several ASX health stocks have...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a small gain. At the time of writing, the benchmark index is up 0.1% to 7,024.3 points. Four ASX shares that have failed to follow the market hi...

The Medical Developments International Ltd (ASX: MVP) share price is drifting deep into the red in early trade on Monday. At the time of writing, the share trades 17% lower at $1.99 following the release of a company announcement. What...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. Morgans takes conservative app...

The ASX 200 is pretty flat, small caps up circa 0.5%  Materials and energy dragging locally Alibaba reports tonight: analysts predicting 30 thieves, down from previous high of 40   Around lunchtime, the major banks started passing on the...

Medical Developments International (MVP) launches a $30 million capital raise to execute further growth The company will aim to raise $15 million from a placement and $15 million from a one-for-9.5 non-renounceable entitlement offer The ne...

The Medical Developments International Ltd (ASX: MVP) share price is on ice today following a company requested trading halt. The ASX granted the trading pause before market open. Prior to being put into the trading halt, the last bid fo...

Medical Developments International (ASX:MVP) has announced a fully underwritten capital raising of $30 million.

In times of great uncertainty the Australian healthcare sector can offer investors plenty of choice, with varying degrees of risk and opportunities. -Australia’s healthcare sector has seen record government investment-Global pandemic has ac...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Medical Developments International (ASX:MVP) has announced the appointment of Tara Eaton as its general counsel and company secretary.

The deep sell down of the US biotech sector has resulted in the valuation of many of the ASX-listed life science plays looking a tad sickly, too. Arguably, many of them were overvalued in the first place. But in many cases the companies ar...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is fighting hard to stay in positive territory. At the time of writing, the benchmark index is up 0.1% to 7,105.7 points. Four ASX shares that are climbing more than most are listed...

Medical Developments International (MVP) shares jump after the US Food and Drug Administration lifts its hold on pain relief drug, Penthrox This means that the company can immediately begin preparing for its phase three US clinical trial...

The ASX 200 Health Index (XHJ) is trading lower by 0.27% at the time of writing, compared to the broader index which is falling by 0.56%. Pain relief specialist Medical Development International (ASX:MVP) announced that the US FDA has uncon...

The Medical Developments International Ltd (ASX: MVP) share price has returned from its trading halt with a bang. In morning trade, the medical device company’s shares are up a massive 32% to $4.50. Why is the Medical Developments Internat...

The Medical Developments International Ltd (ASX: MVP) share price will be on watch on Friday. This follows the release of the healthcare company’s half year results after the market close. Medical Developments International share price on...

The ASX 200 Health Index (XHJ) has fallen by 1.26% at the time of writing, compared to the broader index which is down by 0.12%. Medical device company OncoSil Medical (ASX:OSL) surged as high as 25% up today, after its device was granted a...